Anjali Jha

Anjali Jha

Auto-generated profile, based on publicly available information

Anjali Jha

Nanobioscience Group, Agharkar Research Institute, G. G. Agarkar Road, Pune 411004, India

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2018 in Langmuir
Verified
Journal Article
Closed access
AJAnjali Jha
Anjali Jha
MKMothukuri Ganesh Kumar
Mothukuri Ganesh Kumar
HGHosahudya N. Gopi
Hosahudya N. Gopi
KPKishore M. Paknikar
Kishore M. Paknikar

25 March 2019 in Journal of Materials Chemistry B
Verified
Journal Article
Closed access
PDF file
AJAnjali Jha
Anjali Jha
VGVandana Ghormade
Vandana Ghormade
HKHenry Kolge
Henry Kolge
KPKishore M. Paknikar
Kishore M. Paknikar
Deposition of amyloid β (1–42), i.e. (Aβ1–42), peptide aggregates in the brain is the hallmark of Alzheimer's disease (AD). However, therapeutic strategies specifically targeted towards inhibition of early toxic oligomers and disruption of amyloid aggregates to treat AD remain elusive. Recently, nanoparticle-based therapies for CNS disorders have emerged as an area of considerable interest because of their reach across the blood–brain barrier. Here we study the anti-amyloidogenic activity of two types of chitosan-based nanoparticles, bare chitosan and chitosan copolymerized with PLGA. We show that the chitosan-based nanoparticles strongly inhibit the Aβ1–42 peptide aggregation process and cause substantial disintegration of the pre-formed soluble and insoluble aggregates in vitro. Furthermore, these nanoparticles appear to stabilize the peptides in an α-helical conformation and inhibit the formation of β-sheet structure, which is more prone to form aggregates. The inhibitory effect of chitosan nanoparticles was seen to alleviate the cytotoxicity elicited by Aβ1–42. Interestingly, the observed anti-amyloid activity of bare chitosan nanoparticles is ∼200-fold more potent than polymeric (bulk) chitosan. Moreover, our results also demonstrate that the amyloid inhibition efficiency varies according to the nanoparticle type and the inhibitory activity of the nanoparticles declines considerably when chitosan is copolymerized with PLGA. The observed phenomena could be attributed to the different surface charge present on the two types of nanoparticles. Collectively, our results suggest that chitosan nanoparticles could provide a promising alternative to the curative strategies being developed for treating amyloid-related neurodegenerative disorders.

1 December 2020 in Biophysical Chemistry
Verified
Journal Article
Closed access
MSMadhukar S. Said
Madhukar S. Said
GNGovinda R. Navale
Govinda R. Navale
AYAshok Yadav
Ashok Yadav
NKNilesh Khonde
Nilesh Khonde
SSSandip S Shinde
Sandip S Shinde
AJAnjali Jha
Anjali Jha

12 February 2019 in Biomacromolecules
Verified
Journal Article
Closed access
RRRahi M. Reja
Rahi M. Reja
RPRajat Patel
Rajat Patel
VKVivek Kumar
Vivek Kumar
AJAnjali Jha
Anjali Jha
HGHosahudya N. Gopi
Hosahudya N. Gopi